Clinical Course of Six Children With GNAO1 Mutations Causing a Severe and Distinctive Movement Disorder

• Published in: Pediatric neurology Vol. 59; pp. 81 - 84
• Main Authors: Ananth, Amitha L., MD, Robichaux-Viehoever, Amy, MD, PhD, Kim, Young-Min, ​MD, Hanson-Kahn, Andrea, MS, CGC, Cox, Rachel, MS, CGC, Enns, Gregory M., MB, ChB, Strober, Jonathan, MD, Willing, Marcia, MD, Schlaggar, Bradley L., MD, PhD, Wu, Yvonne W., MD, MPH, Bernstein, Jonathan A., MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2016
• Subjects: Adolescent; ballismus; Child; Child, Preschool; chorea; Disease Progression; Fatal Outcome; Female; GNAO1; GTP-Binding Protein alpha Subunits, Gi-Go - genetics; Humans; Male; movement disorder; Movement Disorders - drug therapy; Movement Disorders - genetics; Movement Disorders - physiopathology; Neurology; Pediatrics; whole exome sequencing; GNAO1; chorea; movement disorder; ballismus; whole exome sequencing
• ISSN: 0887-8994; 1873-5150
• DOI: 10.1016/j.pediatrneurol.2016.02.018

Abstract Objectives Mutations in GNAO1 have been described in 11 patients to date. Although most of these individuals had epileptic encephalopathy, four patients had a severe movement disorder as the prominent feature. We describe the largest series of patients with de novo GNAO1 mutations who have severe chorea, developmental delay, and hypotonia in the absence of epilepsy. Methods Six patients with recurrent missense mutations in GNAO1 as detected by whole exome sequencing were identified at three institutions. We describe the presentation, clinical course, and response to treatment of these patients. Results All six patients exhibited global developmental delay and hypotonia from infancy. Chorea developed by age four years in all but one patient, who developed chorea at 14 years. Treatments with neuroleptics and tetrabenazine were most effective in the baseline management of chorea. The chorea became gradually progressive and marked by episodes of severe, refractory ballismus requiring intensive care unit admissions in four of six patients. Exacerbations indirectly led to the death of two patients. Conclusions Patients with GNAO1 mutations can present with a severe, progressive movement disorder in the absence of epilepsy. Exacerbations may be refractory to treatment and can result in life-threatening secondary complications. Early and aggressive treatment of these exacerbations with direct admission to intensive care units for treatment with anesthetic drips may prevent some secondary complications. However the chorea and ballismus can be refractory to maximum medical therapy.